1. Home
  2. Stocks
  3. Jfllife Share Price

JFL Life Sciences Share Price

Pharmaceuticals Small Cap

₹24.45 +1.15 (4.94%)

05 Nov, 2024 16:52

SIP TrendupStart SIP in JFLLIFE

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹24
  • High
  • ₹24
  • 52 Week Low
  • ₹12
  • 52 Week High
  • ₹25
  • Open Price₹24
  • Previous Close₹23
  • Volume30,000

Investment Returns

  • Over 1 Month + 2.3%
  • Over 3 Month + 8.28%
  • Over 6 Month + 56.53%
  • Over 1 Year + 46.67%
SIP Lightning

Smart Investing Starts Here Start SIP with JFL Life Sciences for Steady Growth!

JFL Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • PEG Ratio
  • Market Cap Cr
  • 81
  • P/B Ratio
  • 2.3
  • Average True Range
  • 0.97
  • EPS
  • 1
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.58
  • RSI
  • 53.51
  • MFI
  • 75.52

JFL Life Sciences Financial

IndicatorMar 24Mar 23
Revenue From Operations [Gross]46.5542.83
Revenue From Operations [Net]46.5542.83
Total Operating Revenues46.5542.83
Total Revenue47.0744.47
Total Expenses43.2740.75
Profit/Loss Before Tax3.803.72
Profit/Loss For The Period3.312.81
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity8.35-9.05
Net Cash Used In Investing Activity-6.070.86
Net Cash Used in Finance Activity-2.318.06
Net Inc/Dec In Cash And Equivalent-0.03-0.13
Cash And Equivalent End Of Year0.030.06
IndicatorMar 24Mar 23
Total Share Capital11.0011.00
Total Non-Current Liabilities1.081.57
Total Current Liabilities19.9815.22
Total Capital And Liabilities56.6449.06
Total Non-Current Assets13.517.93
Total Current Assets43.1341.13
Total Assets56.6449.06
Indicator20242023
EBIT Margin (%)9.9412.00
Return On Capital Employed (%)12.6215.18
Return On Equity (%)9.308.70
Long Term Debt To Equity (%)2.754.30
Book Value/Share (INR)10.679.68
Indicator20242023
EBIT Margin (%)9.9412.00
Return On Capital Employed (%)12.6215.18
Return On Equity (%)9.308.70
Long Term Debt To Equity (%)2.754.30
Book Value/Share (INR)10.679.68

JFL Life Sciences Technicals

EMA & SMA

Current Price
₹24.45
+ 1.15 (4.94%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹22.80
  • 50 Day
  • ₹21.54
  • 100 Day
  • ₹19.68
  • 200 Day
  • ₹17.81

Resistance and Support

23.3 Pivot Speed
  • R3 23.30
  • R2 23.30
  • R1 23.30
  • S1 23.30
  • S2 23.30
  • S3 23.30

Is JFL Life Sciences Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Jfl Life Sciences has an operating revenue of Rs. 155.74 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 8% is okay, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 35% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 45 indicates it belongs to a fair industry group of Medical-Whlsle Drg/Suppl and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

JFL Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-08-02 Bonus issue, Dividend & Fund Raising
2024-05-27 Audited Results
2023-11-08 Quarterly Results
2023-05-27 Audited Results
2022-11-12 Quarterly Results
Date Purpose Remarks
2024-09-24 Bonus Rs.0.00 issue in the ratio of 2:1 of Rs. 10/-.

JFL Life Sciences F&O

JFL Life Sciences Shareholding Pattern

67.47%
28.37%
4.16%
  • NSE Symbol
  • JFLLIFE
  • BSE Symbol
  • Managing Director
  • Mr. Smiral Ashwinkumar Patel
  • ISIN
  • INE0LA901015

JFL Life Sciences FAQs

JFL Life Sciences share price is ₹24 As on 05 November, 2024 | 16:38

The Market Cap of JFL Life Sciences is ₹80.7 Cr As on 05 November, 2024 | 16:38

The P/E ratio of JFL Life Sciences is As on 05 November, 2024 | 16:38

The PB ratio of JFL Life Sciences is 2.3 As on 05 November, 2024 | 16:38

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.